€3.26
0.96% yesterday
L&S, Jul 04, 10:54 pm CET
ISIN
FR0004056851
Symbol
VLA
Sector
Industry

Valneva Stock price

€3.20
-0.85 20.97% 1M
-1.63 33.76% 6M
-1.52 32.29% YTD
-3.49 52.21% 1Y
-8.34 72.31% 3Y
-0.06 1.96% 5Y
-2.08 39.47% 10Y
Paris, Closing price Thu, Jul 04 2024
-0.03 0.93%
ISIN
FR0004056851
Symbol
VLA
Sector
Industry

Key metrics

Market capitalization €448.91m
Enterprise Value €483.94m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.16
P/S ratio (TTM) P/S ratio 2.93
P/B ratio (TTM) P/B ratio 2.37
Revenue growth (TTM) Revenue growth -58.99%
Revenue (TTM) Revenue €152.96m
EBIT (operating result TTM) EBIT €-109.09m
Free Cash Flow (TTM) Free Cash Flow €-236.26m
Cash position €176.64m
EPS (TTM) EPS €-0.18
P/E forward negative
P/S forward 2.53
EV/Sales forward 2.73
Show more

Is Valneva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.

Valneva Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Valneva forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Valneva forecast:

Buy
90%
Hold
10%

Financial data from Valneva

Dec '23
+/-
%
Net Profit -101 -101
29% 29%
-66%
Depreciation and Amortization 18 18
16% 16%
11%
Stock Compensation 5.11 5.11
159% 159%
3%
Operating Cash Flow -214 -214
16% 16%
-139%
Investments 14 14
51% 51%
9%
Dividend Paid - -
-
-
Free Cash Flow -228 -228
19% 19%
-149%

In millions EUR.

Don't miss a Thing! We will send you all news about Valneva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Head office France
CEO Thomas Lingelbach
Employees 676
Founded 1999
Website www.valneva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today